Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses

Ipilimumab is effective for patients with melanoma, but not for those with less immunogenic tumors. We report a phase II trial of ipilimumab with concurrent or sequential stereotactic ablative radiation therapy to metastatic lesions in the liver or lung (). Ipilimumab (every 3 weeks for 4 doses) was...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Cancer Immunol Res
المؤلفون الرئيسيون: Welsh, James W., Tang, Chad, de Groot, Patricia, Naing, Aung, Hess, Kenneth R., Heymach, John V., Papadimitrakopoulou, Vassiliki A., Cushman, Taylor R., Subbiah, Vivek, Chang, Joe Y., Simon, George R., Ramapriyan, Rishab, Barsoumian, Hampartsoum B., Menon, Hari, Cortez, Maria A., Massarelli, Erminia, Nguyen, Quynh, Sharma, Padmanee, Allison, James P., Diab, Adi, Verma, Vivek, Raju, Uma, Shaaban, Sherif G., Dadu, Ramona, Cabanillas, Maria E., Wang, Kelvin, Anderson, Clark, Gomez, Daniel R., Hahn, Stephen, Komaki, Ritsuko, Hong, David S.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2019
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6891218/
https://ncbi.nlm.nih.gov/pubmed/31658994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0793
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة